Answers are grounded in this paper and cite their sources.
Review outlines therapeutic rationales for atopic dermatitis treatments, suggesting targeted biologicals improve outcomes across diverse clinical phenotypes.
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and significantly impacts patients' lives, particularly in its severe forms. AD clinical presentation varies over the course of the disease, throughout different age groups, and across ethnicities. AD is characterized by a spectrum of clinical phenotypes as well as endotypes. Starting from the current description of AD pathogenesis, this review explores the rationale of approved AD therapies from emollients to biologicals and introduces novel promising drugs.
No takes yet. Share an insight, caveat, or question.
Salvati et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: